Astellas Licenses AI-Designed AAV Capsid from Dyno Therapeutics for Skeletal Muscle Gene Therapy
核心洞察
Astellas Pharma has exercised its option to license a novel AI-engineered AAV capsid (搜索) from Dyno Therapeutics (搜索) for therapeutic delivery to skeletal muscle (搜索), triggering a $15 million fee plus potential milestone and royalty payments.
This marks Dyno's second capsid license overall and first muscle-targeted capsid, positioning the company as the first to successfully license AI-designed AAV capsids for both central nervous system (搜索) and muscle gene therapies.
The licensed capsid demonstrates superior skeletal muscle (搜索) targeting in nonhuman primates while leveraging existing AAV9-based manufacturing processes for efficient, large-scale production.
Astellas Pharma Inc. has exercised its option to license a novel adeno-associated virus (AAV) capsid engineered by Dyno Therapeutics (搜索) for therapeutic delivery to skeletal muscle (搜索), marking a significant milestone in AI-powered gene therapy development. The license triggers a $15 million fee for Dyno plus potential milestone and royalty payments under terms established in the companies' 2021 research collaboration.
This represents Dyno's second capsid license overall and first muscle-targeted capsid, following Roche's exercise of an option for a neurological disease (搜索) capsid in January 2025. The achievement positions Dyno as the first company to successfully license AI-designed AAV capsids for both central nervous system (搜索) and muscle gene therapies.
Addressing Core Gene Therapy Challenges
Gene therapies targeting muscle disorders (搜索) have historically faced a fundamental limitation: wild-type AAV capsids do not achieve therapeutic delivery to muscle except at high doses, creating safety risks and significant manufacturing costs that have challenged the field. Traditional capsid discovery approaches rely on rational design or directed evolution, while Dyno applies AI models trained on billions of in vivo measurements to engineer capsids with improved performance.
"Dyno was founded on the thesis that revolutionary AI technologies would enable us to solve longstanding challenges such as engineering AAV capsids for improved gene delivery, and this license is evidence that we're achieving that vision," said Eric Kelsic, Ph.D., Chief Executive Officer and Cofounder of Dyno Therapeutics (搜索).
Superior Performance in Preclinical Studies
The licensed Dyno capsid demonstrates superior skeletal muscle (搜索) targeting in nonhuman primates while leveraging existing AAV9-based manufacturing processes to enable efficient, large-scale production. This compatibility with established manufacturing infrastructure represents a significant advantage for clinical development and commercial scalability.
Dyno's AI-powered platform connects frontier AI agents and foundation models to accelerate cost-effective development of genetic medicine. The platform engineers AAV capsids optimized for selective delivery, liver detargeting, cross-species translatability and manufacturability, trained on billions of in vivo non-human primate measurements.
Expanding Capsid Portfolio
Beyond the Astellas license, Dyno recently launched two additional AAV capsids for central nervous system (搜索) and muscular delivery. The company's Dyno-9zh (搜索) capsid is engineered for efficient blood-brain barrier (搜索) crossing and widespread CNS transduction following intravenous administration across humans, NHPs and mice. At a dose of 3×10¹³ vg/kg, it broadly transduces NHP brain and spinal cord, with up to 50% of neurons transduced in premotor cortex.
"Astellas' decision to license a Dyno muscle capsid validates years of AI platform development and positions this capsid as one of the most promising gene delivery vectors ready for clinical advancement," Kelsic noted. "The Dyno-Astellas partnership reflects Astellas' commitment to investing in innovative new technologies with the potential to transform patient lives by solving for the root causes of genetic disease (搜索)."
The licensing milestone demonstrates the growing commercial validation of AI-powered approaches to genetic medicine development, potentially accelerating the path to more effective and accessible gene therapies for patients with muscle disorders (搜索).